Evaluation of strain coverage of the multicomponent meningococcal serogroup B vaccine (4CMenB) administered in infants according to different immunisation schedules

The 4-component vaccine 4CMenB, developed against invasive disease caused by meningococcal serogroup B, is approved for use in infants in several countries worldwide. 4CMenB is mostly used as 3 + 1 schedule, except for the UK, where a 2 + 1 schedule is used, and where the vaccine showed an effective...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Hum Vaccin Immunother
Autori principali: Biolchi, Alessia, Tomei, Sara, Santini, Laura, Welsch, Jo Anne, Toneatto, Daniela, Gaitatzis, Nikolaos, Bai, Xilian, Borrow, Ray, Giuliani, Marzia Monica, Mori, Elena, Pizza, Mariagrazia
Natura: Artigo
Lingua:Inglês
Pubblicazione: Taylor & Francis 2019
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6605712/
https://ncbi.nlm.nih.gov/pubmed/30352000
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2018.1537756
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi